The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move that strengthens the European biotech sector's outlook, NewAmsterdam Pharma and the Menarini Group announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for its cholesterol treatments. The committee recommends marketing authorization for Ubeslo (obicetrapib monotherapy) and Evlarco (a fixed-dose combination). These therapies target patients with primary hypercholesterolemia or mixed dyslipidemia who find existing treatments insufficient or poorly tolerated.
This regulatory milestone is backed by positive Phase 3 clinical data from the BROADWAY, BROOKLYN, and TANDEM trials, which demonstrated significant efficacy in lowering LDL-C levels. A positive CHMP opinion is a critical precursor to final European Commission approval, potentially opening a major market for these cardiovascular medicines and providing a new oral, non-statin option for high-risk patients.
Regarding market performance, NAMS stood at $32.34 at the close of July 21, 2026, after reaching a day high of $32.44. Investors are now looking toward the formal European Commission decision as the next major catalyst for the stock. In broader context, EU Economic Sentiment data released on July 21 showed a rise to 23.4, significantly outperforming the forecast of 11.2, reflecting a supportive economic backdrop in the region.